| Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer LM Smyth, K Tamura, M Oliveira, EM Ciruelos, IA Mayer, MP Sablin, ... Clinical Cancer Research 26 (15), 3947-3957, 2020 | 92 | 2020 |
| Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis A Barnicle, C Seoighe, JM Greally, A Golden, LJ Egan Epigenetics 12 (8), 591-606, 2017 | 46 | 2017 |
| Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound KN Chi, A Barnicle, C Sibilla, Z Lai, C Corcoran, JC Barrett, CA Adelman, ... Clinical Cancer Research 29 (1), 81-91, 2023 | 42 | 2023 |
| Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1/ENGOT-ov25 trial E Pujade-Lauraine, J Brown, A Barnicle, J Wessen, P Lao-Sirieix, ... JCO Precision Oncology 7, e2200258, 2023 | 41 | 2023 |
| Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis A Poveda, S Lheureux, N Colombo, D Cibula, K Lindemann, J Weberpals, ... Gynecologic oncology 164 (3), 498-504, 2022 | 39 | 2022 |
| Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts A Gris-Oliver, M Palafox, L Monserrat, F Brasó-Maristany, A Òdena, ... Clinical Cancer Research 26 (14), 3720-3731, 2020 | 33 | 2020 |
| Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic … KN Chi, A Barnicle, C Sibilla, Z Lai, C Corcoran, JA Williams, JC Barrett, ... Journal of Clinical Oncology 39 (6_suppl), 26-26, 2021 | 28 | 2021 |
| Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial J Mateo, JS de Bono, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... Journal of Clinical Oncology 42 (5), 571-583, 2024 | 26 | 2024 |
| Homologous recombination repair gene mutation characterization by liquid biopsy: a phase II trial of olaparib and abiraterone in metastatic castrate-resistant prostate cancer TH Carr, C Adelman, A Barnicle, I Kozarewa, S Luke, Z Lai, S Hollis, ... Cancers 13 (22), 5830, 2021 | 25 | 2021 |
| Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 … E Pujade-Lauraine, J Brown, A Barnicle, P Rowe, P Lao-Sirieix, ... Gynecologic Oncology 162, S26-S27, 2021 | 22 | 2021 |
| Impact of DNA damage repair alterations on prostate cancer progression and metastasis N Lukashchuk, A Barnicle, CA Adelman, J Armenia, J Kang, JC Barrett, ... Frontiers in Oncology 13, 1162644, 2023 | 19 | 2023 |
| Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation … S Pignata, A Oza, G Hall, B Pardo, R Madry, D Cibula, J Klat, A Montes, ... Gynecologic Oncology 172, 121-129, 2023 | 11 | 2023 |
| Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim … A Poveda, S Lheureux, N Colombo, D Cibula, K Lindemann, JI Weberpals, ... Journal of Clinical Oncology 38 (15_suppl), 6057-6057, 2020 | 9 | 2020 |
| Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells A Barnicle, C Seoighe, A Golden, JM Greally, LJ Egan Physiological genomics 48 (4), 257-273, 2016 | 8 | 2016 |
| Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair … S Pignata, AM Oza, G Hall, B Pardo, R Madry, D Cibula, J Klat, A Montes, ... Journal of Clinical Oncology 40 (16_suppl), 5519-5519, 2022 | 6 | 2022 |
| ORZORA: maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene … S Pignata, A Oza, G Hall, B Pardo, R Madry, D Cibula, J Klat, A Montes, ... Gynecologic Oncology 162, S29, 2021 | 6 | 2021 |
| Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): final overall … AM Poveda Velasco, S Lheureux, N Colombo, D Cibula, M Elstrand, ... ANNALS OF ONCOLOGY 33 (7), S790-S790, 2022 | 5 | 2022 |
| 1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic … AJ Armstrong, F Saad, A Thiery-Vuillemin, M Oya, ND Shore, N Mehra, ... Annals of Oncology 33, S1168, 2022 | 5 | 2022 |
| Homologous recombination repair gene mutation characterization by liquid biopsy: A phase 2 trial of olaparib and abiraterone in metastatic castrate-resistant prostate cancer … TH Carr, C Adelman, A Barnicle, I Kozarewa, S Luke, Z Lai, S Hollis, ... DOI: https://doi. org/10.3390/cancers13225830, 2021 | 4 | 2021 |
| 740P Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the … K Lindemann, E Škof, N Colombo, A González-Martín, R Davidson, ... Annals of Oncology 32, S738-S739, 2021 | 3 | 2021 |
